Division of Novartis AG
Latest From Ciba-Geigy Corp.
After publication of ATHOS-3 study results, agency received several requests from medical community for emergency use in hospitalized patients with shock and hypotension unresponsive to available therapy, spurring FDA to take an approval action two months ahead of user fee goal date.
The agency has 11 research projects under way, including a $2 million study of online Rx drug promotion; pharma spending on direct-to-consumer advertising declined in 2012 with biggest spends on Cymbalta and Cialis ads.
Wolfe steps down to become senior advisor but remains a vocal critic of the pharmaceutical industry and FDA, as his appearance at the Avandia advisory committee meeting demonstrated.
Biotech focused on role of carbohydrates in biological processes completes Phase II program of lead candidate for sickle cell disease. Under a 2011 partnership, Pfizer takes over development of GMI-1070 in Phase III.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Novartis AG
- Senior Management
Douglas Watson, Pres. & CEO
William Huebner, Dir. Portfolio Mgmt, Drug Development
Stephen Leventhal, Chief, International Product Development
- Contact Info
Phone: (914) 785-4050
520 White Plains Rd.
Tarrytown, NY 10591
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.